Conclusions Short-term ( 4–12 weeks ) supplementation with vitamin D is associated with lower fasting glucose levels in ESRD with no change in fasting insulin levels .
Abstract Purpose We tested whether short-term vitamin D supplementation improves insulin resistance in patients with kidney disease , a condition with little intrinsic vitamin D activity .
Effect of Activated Vitamin D on Glucoparameters in HCV Seropositive and Seronegative Patients on Chronic Hemodialysis
Introduction : Many studies support the role of vitamin D in the pathogenesis of both types of diabetes . Pancreatic tissues express the vitamin D receptor ( VDR ) and vitamin D-binding protein ; some allelic variations in genes involved in vitamin D metabolism and VDR are associated with glucose intolerance , defective insulin secretion , and sensitivity . Epidemiological links have been established between type 2 diabetes mellitus ( DM ) and hepatitis C virus ( HCV ) infection . Aim : To explore the possible therapeutic potential of pharmacologic doses of 1-α-hydroxy vitamin D therapy in improving pancreatic β-cell function in HCV seropositive hemodialysis ( HD ) patients . Patients and methods : Twenty HCV seropositive HD patients and 20 HCV seronegative patients as control group were r and omly selected from HD units .  1-α-Hydroxy vitamin D therapy was administrated in the dose ranged from 0.25 to 0.5 μg/day for 3 months  . Corrected total serum calcium , phosphorus , intact parathyroid hormone ( iPTH ) , 25-hydroxy vitamin D [ 25(OH ) vitamin D ] , 1,25-dihydroxy vitamin D , and glucoparameters [ fasting blood glucose , glycohemoglobin test ( HbA1c% ) , homeostatic model assessment (HOMA)-insulin resistance , and HOMA-β-cell function% ( B% ) ] were measured under basal conditions and after 3 months of therapy . Results : There was highly significant improvement in the concentrations of fetal bovine serum ( FBS ) , serum insulin , HbA1c% , 25(OH ) vitamin D , and HOMA-β-cell function in HCV seropositive and HCV seronegative groups after oral 1-alphacalcidiol therapy ( p < 0.001 ) . Positive correlation exists between the percentage increase in serum insulin and that in HOMA-β-cell function versus 25(OH ) vitamin D ( p < 0.021 and p < 0.027 , respectively ) in HCV negative group . Conclusion : 1-α-Hydroxy vitamin D oral therapy may improve glycemic control in HCV seropositive and HCV seronegative HD patients
Conclusions Short-term ( 4–12 weeks ) supplementation with vitamin D is associated with lower fasting glucose levels in ESRD with no change in fasting insulin levels .
Abstract Purpose We tested whether short-term vitamin D supplementation improves insulin resistance in patients with kidney disease , a condition with little intrinsic vitamin D activity .